曲妥珠单抗德鲁替康在HER2异质性肿瘤中的临床前PET显像
本研究用64Cu标记曲妥珠单抗德鲁替康(T-DXd),在11种肿瘤模型中评估不同HER2表达水平的摄取,并观察治疗期间摄取变化与肿瘤体积变化的关系。结果显示该探针可检测低HER2肿瘤中的抗体药物偶联物蓄积,可能作为早期疗效影像生物标志物。
要点
- 64Cu标记T-DXd在11种肿瘤模型中均可显像,平均摄取为7.45±1.28至19.10±2.50 %ID/mL。
- 预注射曲妥珠单抗或帕妥珠单抗不影响64Cu-NOTA-T-DXd的肿瘤摄取。
- 治疗第1至2周间,64Cu-NOTA-T-DXd摄取变化与肿瘤体积变化呈正相关(P<0.01)。
核心结论
- 64Cu-NOTA-T-DXd PET可检测低HER2蛋白水平肿瘤中的抗体药物偶联物蓄积。
- 该显像可能提供与T-DXd治疗反应相关的早期影像生物标志物。
研究设计与样本
- 临床前研究,通过赖氨酸偶联制备NOTA偶联的T-DXd或曲妥珠单抗并用64Cu标记。
- 在11种肿瘤模型(涵盖5种肿瘤类型,含细胞异种移植、患者来源异种移植和同系模型,皮下及原位)中行PET/CT并定量肿瘤摄取。
- 治疗研究中,荷CT26-hHER2肿瘤(免疫组化评分2+、HER2表达异质)小鼠每周共注射治疗性T-DXd(6 mg/kg)与显像剂量64Cu-NOTA-T-DXd(4 mg/kg),总T-DXd剂量10 mg/kg。
主要发现
- 64Cu-NOTA-T-DXd放射化学纯度至少98%。
- 纯化探针与细胞结合呈浓度依赖性,HER2蛋白水平与结合的T-DXd呈正相关。
- NOTA偶联不影响T-DXd与癌细胞结合及细胞毒性。
- 64Cu-NOTA-T-DXd平均肿瘤摄取在不同模型间为7.45±1.28至19.10±2.50 %ID/mL,与母体抗体64Cu标记曲妥珠单抗相似。
- 在免疫健全小鼠的CT26.hHER2肿瘤中,治疗第1至2周间64Cu-NOTA-T-DXd摄取变化与肿瘤体积变化呈正相关(P<0.01)。
关键数值与推荐
- HER2蛋白水平与结合的T-DXd呈正相关。
- CT26-hHER2肿瘤免疫组化评分为2+。
- 治疗性T-DXd每周6 mg/kg与显像剂量4 mg/kg共注射,总剂量10 mg/kg。
临床怎么用
- 临床前证据提示HER2靶向PET显像可用于无创评估T-DXd在低HER2肿瘤中的递送。
- 治疗早期显像摄取变化可能与肿瘤体积变化相关,支持进一步探索影像生物标志物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Trastuzumab deruxtecan (T-DXd) has clinical activity in human epidermal growth factor receptor 2 (HER2)-low and -ultralow tumors in addition to HER2-positive tumors. However, no consistent correlation has been observed between traditional HER2 scoring criteria and response to T-DXd in HER2-low and HER2-ultralow tumors. There is a need for complementary approaches to monitor T-DXd delivery in vivo and potentially improve understanding of which tumors may benefit from T-DXd therapy. This study evaluated tumor uptake of radiolabeled T-DXd in tumors with varying HER2 protein levels using PET in treatment-naïve tumors and during T-DXd therapy. Methods: Chelator-conjugated T-DXd or trastuzumab was prepared via conventional lysine conjugation and radiolabeled with 64Cu. The binding and in vitro cytotoxicity of the conjugates were determined in cancer cell lines. PET/CT was performed across 11 tumor models (representing 5 tumor types), including cell xenografts, patient-derived xenografts, and syngeneic models in both subcutaneous and orthotopic models. Image-based tumor uptake of the radiolabeled antibodies was quantified in all models. In the treatment studies, mice bearing CT26-hHER2 tumors that express heterogeneous HER2 with an immunohistochemistry score of 2+ levels received weekly coinjections of therapeutic T-DXd (6 mg/kg) together with imaging-dose [64Cu]Cu-NOTA-T-DXd (4 mg/kg), corresponding to a total T-DXd administered dose of 10 mg/kg. Results: [64Cu]Cu-NOTA-T-DXd was obtained at a radiochemical purity of at least 98%. Purified [64Cu]Cu-NOTA-T-DXd bound to cells in a concentration-dependent manner and had a positive correlation between HER2 protein levels and bound T-DXd. Conjugation of T-DXd to NOTA did not affect T-DXd binding or cytotoxicity in cancer cells. [64Cu]Cu-NOTA-T-DXd mean tumor uptake varied across models (7.45 ± 1.28 to 19.10 ± 2.50 %ID/mL), and the mean uptake was similar to that of the parental antibody 64Cu-labeled trastuzumab. Preimaging doses of either trastuzumab or pertuzumab did not affect [64Cu]Cu-NOTA-T-DXd uptake in tumors. There was a positive correlation between the change in [64Cu]Cu-NOTA-T-DXd uptake and the change in tumor volume between weeks 1 and 2 of T-DXd treatment (P < 0.01) in CT26.hHER2 tumors grown in immunocompetent mice. Conclusion: [64Cu]Cu-NOTA-T-DXd PET detects antibody-drug accumulation in tumors with low HER2 protein levels and may provide an early imaging biomarker associated with response. These studies show the potential of using HER2-targeted imaging in preclinical models to noninvasively assess antibody-drug conjugate delivery and explore imaging-based biomarkers associated with T-DXd response.
引用
- Benton A, Simó C, Luo C, et al. Preclinical PET Imaging of Trastuzumab Deruxtecan in Tumors with Heterogeneous HER2 Expression. J Nucl Med. 2026. PMID: 42914177. doi:10.2967/jnumed.126.272783
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。